reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.